To our excitement, we observed in this study that SGD administration not only reduced CD68+ M1 microglia and M1 markers (IL-1a, IL-1b, and IL-6) but also significantly elevated the levels of Arg-1+ M2 microglia and the M2 marker IL-10. The gene discussed is CD68; the disease is specific granule deficiency.